The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity

References

• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54
   PubMed Web of Science ®Google Scholar
• Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer 2005;12(Suppl 1):S17-S2710
   PubMed Web of Science ®Google Scholar
• Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453-710
   PubMed Web of Science ®Google Scholar
• Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59
   PubMed Web of Science ®Google Scholar
• Song QB, Wang Q, Hu WG. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis. World J Gastroenterol 2015;21:4365-72
   PubMed Web of Science ®Google Scholar
• Zahonero C, Sanchez-Gomez P. EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy. Cell Mol Life Sci 2014;71:3465-88.
   PubMed Web of Science ®Google Scholar
• Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Canc Res 1997;57:4838-48
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Lynch TJ. The evolving story of the epidermal growth factor receptor as a target for non-small-cell lung cancer. Clin Adv Hematol Oncol 2004;2:786-7
   PubMedGoogle Scholar
• Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Kabbinavar F, Eisen T, et al. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2011;29:3567-73
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44
   PubMed Web of Science ®Google Scholar
• Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-41
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sheng J, Kang S, et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLoS One 2014;9:e107161
   PubMed Web of Science ®Google Scholar
• Wang H, Huang J, Yu X, et al. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. J Cancer Res Clin Oncol 2014;140:1901-9
   PubMed Web of Science ®Google Scholar
• Rosell R, Molina MA, Serrano MJ. EGFR mutations in circulating tumour DNA. Lancet Oncol 2012;13:971-3
   PubMed Web of Science ®Google Scholar
• Fjällskog MLH, Lejonklou MH, Öberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Canc Res 2003;9:1469-73
   PubMed Web of Science ®Google Scholar
• Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 2003;11:305-9
   PubMed Web of Science ®Google Scholar
• Xiong HQ. Molecular targeting therapy for pancreatic cancer. Canc Chemother Pharmacol 2004;54:S69-S77
   PubMed Web of Science ®Google Scholar
• Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:E1-8
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Vaccaro V, Bria E, Sperduti I, et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013;19:4511-19
   PubMed Web of Science ®Google Scholar
• López R, Méndez CM, Fernández MJ, et al. Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). Anticancer Res 2013;33:717-23
   PubMed Web of Science ®Google Scholar
• Stepanski EJ, Reyes C, Walker MS, et al. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas 2013;42:32-6
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck J, Galdermans D, Bustin F, et al. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study). Eur J Cancer Care Engl 2014;23:370-9
   PubMed Web of Science ®Google Scholar
• Kaburagi T, Satoh H, Hayashihara K, et al. Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer. Oncol Lett 2013;5:435-9
   PubMed Web of Science ®Google Scholar
• Lee J, Jang K-T, Ki C-S, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007;109:1561-9
   PubMed Web of Science ®Google Scholar
• Kwak EL, Jankowski J, Thayer SP, et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006;12:4283-7
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703
   PubMed Web of Science ®Google Scholar
• Ryu JK. Recent advances in palliative chemotherapy for unresectable pancreatic cancer. Korean J Gastroenterol 2015;66:150-3
   PubMedGoogle Scholar
• Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35
   PubMed Web of Science ®Google Scholar
• Ng SSW, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer 2002;777-83
   Web of Science ®Google Scholar
• Wang JP, Wu CY, Yeh YC, et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 2015;6:18162-73
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Diaz Beveridge R, Alcolea V, Aparicio J, et al. Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice. J Pancreas 2014;15:19-24
   PubMedGoogle Scholar
• Miyabayashi K, Ijichi H, Mohri D, et al. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res 2013;73:2221-34
   PubMed Web of Science ®Google Scholar
• Fan KY, Gogineni H, Zaboli D, et al. Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. Ann Surg Oncol 2012;19:1980-7
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010;106:349-54
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-7
   PubMed Web of Science ®Google Scholar
• Yung WK, Vredenburgh JJ, Cloughesy TF, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 2010;12:1061-70
   PubMed Web of Science ®Google Scholar
• Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010;98:93-9
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Abrey LE, Lassman AB, et al. North American Brain Tumor Consortium. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme post radiation therapy. Neuro Oncol 2010;12:95-103
   PubMed Web of Science ®Google Scholar
• Kesavabhotla K, Schlaff CD, Shin B, et al. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. J Exp Ther Oncol 2012;10:71-81
   PubMedGoogle Scholar
• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70
   PubMed Web of Science ®Google Scholar
• Geoerger B, Hargrave D, Thomas F, et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 2011;13:109-18
   PubMed Web of Science ®Google Scholar
• Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-56
   PubMed Web of Science ®Google Scholar
• Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park) 2006;20(Suppl 2):26-34
   PubMedGoogle Scholar
• Roé E, García Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab orerlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006;55:429-37
   PubMed Web of Science ®Google Scholar
• Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol 2013;69:463-72
   PubMed Web of Science ®Google Scholar
• Luu M, Boone SL, Patel J, et al. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clin Exp Dermatol 2011;36:733-8
   PubMed Web of Science ®Google Scholar
• Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 2009;43:1658-66
   PubMed Web of Science ®Google Scholar
• Jia Y, Lacouture ME, Su X, Wu S. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol 2009;7:211-17
   PubMedGoogle Scholar
• Rozensztajn N, Ruppert AM, Lavole A, et al. Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. Cancer Med 2014;3:61-9
   PubMed Web of Science ®Google Scholar
• Aranda E, Manzano JL, Rivera F, et al. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol 2012;23:1919-25
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012;78:8-15
   PubMed Web of Science ®Google Scholar
• Fiala O, Pesek M, Finek J, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma 2013;60:26-32
   PubMed Web of Science ®Google Scholar
• Tiseo M, Andreoli R, Gelsomino F, et al. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2014;83:265-71
   PubMed Web of Science ®Google Scholar
• Fukudo M, Ikemi Y, Togashi Y, et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 2013;52:593-609
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Kudoh S, Ohe Y, et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 2012;7:1296-303
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. Available at: http://ctep.cancer.gov [Last accessed August 9, 2006]
   Google Scholar
• Lacouture ME, Lai SE. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006;155:852-4
   PubMed Web of Science ®Google Scholar
• Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005;3:599-606
   PubMedGoogle Scholar
• Martínez E, Martínez M, Rico M, et al. Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial. Onco Targets Ther 2016;9:1057-66
   PubMed Web of Science ®Google Scholar
• Kubota K, Nishiwaki Y, Tamura T, et al. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 2008;3:1439-45
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology–oncology perspective. Skin Therapy Lett 2007;12:1-5
   PubMedGoogle Scholar
• Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-21
   PubMed Web of Science ®Google Scholar
• Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010;16:4452-60
   PubMed Web of Science ®Google Scholar
• Bangsgaard N, Houtkamp M, Schuurhuis DH, et al. Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor. PLoS One 2012;7:e39706
   PubMed Web of Science ®Google Scholar
• Wallach D, Vignon-Pennamen MD. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol 2006;55:1066-71
   PubMed Web of Science ®Google Scholar
• Gales D, Clark C, Manne U, Samuel T. The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol 2013;9:859154
   Google Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14:218-28
   PubMed Web of Science ®Google Scholar
• Strieter RM, Standiford T, Chensue SW, et al. Induction and regulation of interleukin-8 gene expression. Adv Exp Med Biol 1991;305:23-30
   PubMedGoogle Scholar
• Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001;12:375-91
   PubMed Web of Science ®Google Scholar
• Baggiolini M, Loetscher P, Moser B. Interleukin-8 and the chemokine family. Int J Immunopharmacol 1995;17:103-8
   PubMed Web of Science ®Google Scholar
• Shi Q, Xiong Q, Le X, Xie K. Regulation of interleukin-8 expression by tumor-associated stress factors. J Interferon Cytokine Res 2001;21:553-66
   PubMed Web of Science ®Google Scholar
• Campbell LM, Maxwell PJ, Waugh DJ. Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer. Pharmaceuticals (Basel) 2013;6:929-59
   PubMedGoogle Scholar
• Desbaillets I, Diserens AC, Tribolet N, et al. Upregulation of interleukin-8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 1997;186:1201-12
   PubMed Web of Science ®Google Scholar
• Singh JK, Simões BM, Howell SJ, et al. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 2013;15:210
   PubMed Web of Science ®Google Scholar
• Singh JK, Farnie G, Bundred NJ, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res 2013;19:643-56
   PubMed Web of Science ®Google Scholar
• Tang KH, Ma S, Lee TK, et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012;55:807-20
   PubMed Web of Science ®Google Scholar
• Chikamatsu K, Takahashi G, Sakakura K, et al. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck 2011;33:208-15
   PubMed Web of Science ®Google Scholar
• Infanger DW, Cho Y, Lopez BS, et al. Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res 2013;73:7079-89
   PubMed Web of Science ®Google Scholar
• Bonavia R, Inda MM, Vandenberg S, et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene 2012;31:4054-66
   PubMed Web of Science ®Google Scholar
• Kang SH, Chess-Williams R, Anoopkumar-Dukie S, McDermott C. Induction of inflammatory cytokines and alteration of urothelial ATP, acetylcholine and prostaglandin E2 release by doxorubicin. Eur J Pharmacol 2013;700:102-9
   PubMed Web of Science ®Google Scholar
• Luo Y, Ellis LZ, Dallaglio K, et al. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol 2012;132:2440-50
   PubMed Web of Science ®Google Scholar
• Wilson C, Wilson T, Johnston PG, et al. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 2008;7:2649-61
   PubMed Web of Science ®Google Scholar
• Wilson C, Purcell C, Seaton A, et al. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappa B transcription and evasion of apoptosis. J Pharmacol Exp Ther 2008;327:746-59
   PubMed Web of Science ®Google Scholar
• Reers S, Pfannerstill AC, Rades D, et al. Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer. Anticancer Res 2013;33:2481-9
   PubMed Web of Science ®Google Scholar
• Wan S, Pestka S, Jubin RG, et al. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One 2012;7:32542
   PubMed Web of Science ®Google Scholar
• Merighi S, Simioni C, Gessi S, et al. A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia 2009;11:1064-73
   PubMed Web of Science ®Google Scholar
• Dong H, Zhang Y, Xi H. The effects of epidural anaesthesia and analgesia on natural killer cell cytotoxicity and cytokine response in patients with epithelial ovarian cancer undergoing radical resection. J Int Med Res 2012;40:1822-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang J, Gao Y, et al. Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol 2005;2:365-72
   PubMed Web of Science ®Google Scholar
• Wang Y, Qu Y, Niu XL, et al. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011;56:365-75
   PubMed Web of Science ®Google Scholar
• Merritt WM, Lin YG, Spannuth WA, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008;100:359-72
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu RC, Zhang XL, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 2012;59:145-55
   PubMed Web of Science ®Google Scholar
• Cho SC, Rhim JH, Choi HR, et al. Protective effect of 4,4’-diaminodiphenylsulfone against paraquat-induced mouse lung injury. Exp Mol Med 2011;43:525-37
   PubMed Web of Science ®Google Scholar
• Serizawa M, Takahashi T, Yamamoto N, Koh Y. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. J Thorac Oncol 2013;8:259-69
   PubMed Web of Science ®Google Scholar
• Werther K, Bülow S, Hesselfeldt P, et al. VEGF concentrations in tumour arteries and veins from patients with rectal cancer. APMIS 2002;110:646-50
   PubMed Web of Science ®Google Scholar
• Svendsen MN, Lykke J, Werther K, et al. Concentrations of VEGF and VEGFR1 in paired tumor arteries and veins in patients with rectal cancer. Oncol Res 2004;14:611-15
   PubMed Web of Science ®Google Scholar
• Kast RE, Lefranc F, Karpel-Massler G, Halatsch ME. Why dapsone stops seizures and may stop neutrophils’ delivery of VEGF to glioblastoma. Br J Neurosurg 2012;26:813-17
   PubMed Web of Science ®Google Scholar
• Kast RE, Scheuerle A, Wirtz CR, et al. The rationale of targeting neutrophils with dapsone during glioblastoma treatment. Anticancer Agents Med Chem 2011;11:756-61
   PubMed Web of Science ®Google Scholar
• García-Román J, Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett 2013;335:259-69
   PubMed Web of Science ®Google Scholar
• Lee TH, Avraham H, Lee SH, Avraham S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 2002;277:10445-51
   PubMed Web of Science ®Google Scholar
• Scapini P, Lapinet-Vera JA, Gasperini S, et al. The neutrophil as a cellular source of chemokines. Immunol Rev 2000;177:195-203
   PubMed Web of Science ®Google Scholar
• Kasama T, Miwa Y, Isozaki T, et al. Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Curr Drug Targets Inflamm Allergy 2005;4:273-9
   PubMedGoogle Scholar
• Schruefer R, Lutze N, Schymeinsky J, Walzog B. Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am J Physiol Heart Circ Physiol 2005;288:H1186-92
   PubMed Web of Science ®Google Scholar
• Lan CC, Wu CS, Huang SM, et al. High-glucose environment enhanced oxidative stress and increased interleukin-8 secretion from keratinocytes: new insights into impaired diabetic wound healing. Diabetes 2013;62:2530-8
   PubMed Web of Science ®Google Scholar
• Infanger DW, Cho Y, Lopez BS, et al. Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Canc Res 2013;73:7079-89
   PubMed Web of Science ®Google Scholar
• Tingle MD, Mahmud R, Maggs JL, et al. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man. J Pharmacol Exp Ther 1997;283:817-23
   PubMed Web of Science ®Google Scholar
• Uetrecht J, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988;245:274-9
   PubMed Web of Science ®Google Scholar
• Borges VR, Simon A, Sena AR, et al. Nanoemulsion containing dapsone for topical administration: a study of in vitro release and epidermal permeation. Int J Nanomedicine 2013;8:535-44
   PubMed Web of Science ®Google Scholar
• Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res 2014;306:103-24
   PubMed Web of Science ®Google Scholar
• Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin 2001;19:79-86
   PubMed Web of Science ®Google Scholar
• Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993;129:507-13
   PubMed Web of Science ®Google Scholar
• Grunwald MH, Amichai B. Dapsone the treatment of infectious and inflammatory diseases in dermatology. Int J Antimicrob Agents 1996;7:187-92
   PubMed Web of Science ®Google Scholar
• Opravil M, Joos B, Lüthy R. Levels of dapsone and pyrimethamine in serum uring once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob Agents Chemother 1994;38:1197-9
   PubMed Web of Science ®Google Scholar
• Swain AF, Ahmad RA, Rogers HJ, et al. Pharmacokinetic observations on dapsone in dermatitis herpetiformis. Br J Dermatol 1983;108:91-8
   PubMed Web of Science ®Google Scholar
• Zuidema J, Hilbers-Modderman ES, Merkus FW. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986;11:299-315
   PubMed Web of Science ®Google Scholar
• Rich JD, Mirochnick M. Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis. Diagn Microbiol Infect Dis 1996;24:77-9
   PubMed Web of Science ®Google Scholar
• Piette EW, Werth VP. Dapsone in the management of autoimmune bullous diseases. Immunol Allergy Clin North Am 2012;32:317-22
   PubMed Web of Science ®Google Scholar
• Monteiro LM, Lione VF, do Carmo FA, et al. Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. Int J Nanomedicine 2012;7:5175-82
   PubMed Web of Science ®Google Scholar
• Cohen PR. Neutrophilic dermatoses: a review of current treatment options. Am J Clin Dermatol 2014;10:301-12
   Web of Science ®Google Scholar
• Booth SA, Moody CE, Dahl MV, et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992;98:135-40
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007;33:67-77
   PubMed Web of Science ®Google Scholar
• Shimanovich I, Mihai S, Oostingh GJ, et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by auto antibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 2004;204:519-27
   PubMed Web of Science ®Google Scholar
• Study of prophylactic topical dapsone 5% gel versus moisturizer for cetuximab-induced papulopustular (acneiform) rash in patients with mCRC or HNSCC without previous or concurrent RT. Memorial Sloan Kettering Cancer Center. Available at: https://clinicaltrials.gov/ct2/show/NCT01931150 [last accessed September 2015]
   Google Scholar
• Tan J. Dapsone 5% gel: a new option in topical therapy for acne. Skin Therapy Lett 2012;17:1-3
   PubMedGoogle Scholar
• Bakkour W, Chularojanamontri L, Motta L, Chalmers RJ. Successful use of dapsone for the management of circinate balanitis. Clin Exp Dermatol 2014;39:333-5
   PubMed Web of Science ®Google Scholar
• Schmidt E, Reimer S, Kruse N, et al. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 2001;124:157-62
   PubMed Web of Science ®Google Scholar
• Abe M, Shimizu A, Yokoyama Y, et al. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-alpha production from activated mononuclear cells on cutaneous lupus erythematosus. Clin Exp Dermatol 2008;33:759-63
   PubMed Web of Science ®Google Scholar
• Kanoh S, Tanabe T, Rubin BK. Dapsone inhibits IL-8 secretion from human bronchial epithelial cells stimulated with lipopolysaccharide and resolves airway inflammation in the ferret. Chest 2011;140:980-90
   PubMed Web of Science ®Google Scholar
• Kast RE. Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer. Oncol Res 2009;17:383-6
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye F, Yamada K, et al. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Mol Cancer Res 2011;9:1668-85
   PubMed Web of Science ®Google Scholar
• Patel T, McKeage K. Macitentan: first global approval. Drugs 2014;74:127-33
   PubMed Web of Science ®Google Scholar
• Paolillo M, Russo MA, Curti D, et al. Endothelin B receptor antagonists block proliferation and induce apoptosis in glioma cells. Pharmacol Res 2010;61:306-15
   PubMed Web of Science ®Google Scholar
• Fang KM, Wang YL, Huang MC, et al. Expression of macrophage inflammatory protein-1α and monocyte chemoattractant protein-1 in glioma-infiltrating microglia: involvement of ATP and P2X7 receptor. J Neurosci Res 2011;89:199-211
   PubMed Web of Science ®Google Scholar
• Weigert A, Sekar D, Brüne B. Tumor-associated macrophages as targets for tumor immunotherapy. Immunotherapy 2009;1:83-95
   PubMed Web of Science ®Google Scholar
• Hau P, Jachimczak P, Schlaier J, Bogdahn U. TGF-β2 signaling in high-grade gliomas. Curr Pharm Biotechnol 2011;12:2150-7
   PubMed Web of Science ®Google Scholar
• Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA. TGF-β as a therapeutic target in high grade gliomas-promises and challenges. Biochem Pharmacol 2013;85:478-85
   PubMed Web of Science ®Google Scholar
• Stiles JD, Ostrow PT, Balos LL, et al. Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 1997;56:435-9
   PubMed Web of Science ®Google Scholar
• Vergara D, Merlot B, Lucot JP, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Let 2010;291:59-66
   PubMed Web of Science ®Google Scholar
• Wozel G, Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 1995;8:196-202
   PubMedGoogle Scholar
• Morin P Jr, Ferguson D, LeBlanc LM, et al. NMR metabolomics analysis of the effects of 5-lipoxygenase inhibitors on metabolism in glioblastomas. J Proteome Res 2013;12:2165-76
   PubMed Web of Science ®Google Scholar
• Ishii K, Zaitsu M, Yonemitsu N, et al. 5-lipoxygenase pathway promotes cell proliferation in human glioma cell lines. Clin Neuropathol 2009;28:445-52
   PubMed Web of Science ®Google Scholar
• Bishayee K, Khuda-Bukhsh AR. 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy. Acta Biochim Biophys Sin (Shanghai) 2013;45:709-19
   PubMed Web of Science ®Google Scholar
• Wen Z, Liu H, Li M, et al. Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene 2015;34:1241-52
   PubMed Web of Science ®Google Scholar
• Takashima N, Kimura T, Watanabe N, et al. Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash. Onkologie 2012;35:747-52
   PubMedGoogle Scholar